.jpg)
PYRIDAZIN-3(2H)-ONE DERIVATIVES AS MONOAMINE OXIDASE SELECTIVE ISOFORM B INHIBITORS (AS AMENDED)
US2018215718
The present invention refers to pyridazin-3(2H)-one derivatives of general structure I, II and III, which are selective MAO-B inhibitors, and to the use thereof for preparing medicaments intended to treat disorders derived from MAO-B hyperactivity, particularly degenerative disorders of the central nervous system (CNS), such as Parkinson's disease (PD), Alzheimer's disease (AD) and other dementias. These are pyridazin-3(2H)-one derivatives having dithiocarbamate moieties bonded to position 4, 5 or 6 through an alkyl chain of variable length (n=1, 2, 3). This invention is also directed to the preparation of said compounds.
The compounds of the present invention or their salts could be used by the pharmaceutical industry for the preparation of medicaments to treat disorders resulting from MAO-B hyperactivity, including neurodegenerative diseases, such as Parkinson´s and Alzheimer’s diseases and other dementias.
This invention is concerned essentially with pyridazinone derivatives substituted at C4, C5 or C6 with dithiocarbamate fragments that are selective MAO-B inhibitors, and their use for the preparation of medicaments for treating disorders resulting from MAO-B hyperactivity, including neurodegenerative diseases, such as Parkinson´s and Alzheimer’s diseases and other dementias. <p>
The present invention provides novel pyridazin-3(2H)-one derivatives substituted at C4, C5 or C6 with several dithiocarbamate moieties that selectively inhibit the MAO-B activity and whose structure is unrelated to those currently available.